Head to Head Contrast: Prenetics Global (PRE) and Its Rivals

Prenetics Global (NASDAQ:PRE) is one of 55 publicly-traded companies in the “Personal Care Products” industry, but how does it contrast to its rivals? We will compare Prenetics Global to related businesses based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Prenetics Global and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-47.43%	-21.41%	-15.56%
Prenetics Global Competitors	-4.30%	-61.80%	0.37%

Earnings & Valuation

This table compares Prenetics Global and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Prenetics Global	$92.39 million	-$37.71 million	-3.97
Prenetics Global Competitors	$7.92 billion	$1.11 billion	10.59

Prenetics Global’s rivals have higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Prenetics Global and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1	0	6	1	2.88
Prenetics Global Competitors	905	2945	3664	229	2.42

Prenetics Global currently has a consensus target price of $37.17, indicating a potential upside of 125.12%. As a group, “Personal Care Products” companies have a potential upside of 0.17%. Given Prenetics Global’s stronger consensus rating and higher probable upside, research analysts clearly believe Prenetics Global is more favorable than its rivals.

Risk and Volatility

Prenetics Global has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Prenetics Global’s rivals have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 48.6% of shares of all “Personal Care Products” companies are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 11.7% of shares of all “Personal Care Products” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Prenetics Global rivals beat Prenetics Global on 8 of the 13 factors compared.

About Prenetics Global

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.